All news

Canaccord Genuity maintains Aclaris Therapeutics at Buy, raises price target to

Alpha Vantage · TradingView · · AI-summarised by FinFlash

Canaccord Genuity has reiterated its Buy rating for Aclaris Therapeutics (ACRS) and increased its price target from

Read original source

ACRS company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.